Zanamivir for influenza in adults and children: systematic review of clinical study reports and summary of regulatory comments
about
How Can Viral Dynamics Models Inform Endpoint Measures in Clinical Trials of Therapies for Acute Viral Infections?Neuraminidase inhibitor therapy in a military population.Neuraminidase Inhibitors and Hospital Mortality in British Patients with H1N1 Influenza A: A Re-Analysis of Observational Data.Antiviral medications for influenzaEvaluation of the Becton Dickinson Rapid Influenza Diagnostic Tests in Outpatients in Germany during Seven Influenza Seasons.Burden of Influenza-Related Hospitalizations and Attributable Mortality in Pediatric Acute Lymphoblastic Leukemia.A diagnostic one-step real-time reverse transcription polymerase chain reaction method for accurate detection of influenza virus type A.Targeting eicosanoid pathways in the development of novel anti-influenza drugs.Antiviral treatment of influenza in South Korea.Toward antiviral therapy/prophylaxis for rhinovirus-induced exacerbations of chronic obstructive pulmonary disease: challenges, opportunities, and strategies.Emergence of Oseltamivir-Resistant H7N9 Influenza Viruses in Immunosuppressed Cynomolgus Macaques.ECDC expert opinion on efficacy and effectiveness of neuraminidase inhibitors published for public consultation.Diagnosis and treatment of community-acquired pneumonia in adults: 2016 clinical practice guidelines by the Chinese Thoracic Society, Chinese Medical Association.Zanamivir Diminishes Lung Damage in Influenza A Virus-infected Mice by Inhibiting Nitric Oxide Production.
P2860
Q30357603-DCF25D0B-4A75-4504-9BFB-470CC5F71BA4Q30374549-CF3D3D27-8366-49DE-BFAB-10D929703B8FQ30392472-0C3133B5-1747-40A1-A6AB-31879667B1F3Q35412828-E15F4D58-0AD0-454E-8D67-B08F12E1B148Q35642071-4CBCF7D7-3EBA-40C4-8467-797CB24B3B37Q36377400-7ADE6E25-BAF9-4789-948A-C013CD455B45Q37412693-9BB53EC3-C455-4D1E-8E06-60014AC68955Q38255645-9D46E96B-8D50-49A9-BA54-81B38B31561CQ38401883-C119CF07-C838-4B6A-9600-7EC685FBD781Q38590038-7386B85D-DFC2-4962-A595-A1A0615B4030Q41933615-E36970BA-14F0-4C12-ABDD-59466C648D12Q42924849-B9A63A41-A228-4F74-A2EF-8C57970566EFQ53516441-C233A1FF-FD96-4BED-B7A9-FAD1F31552C0Q55441775-BCDD31D3-89A2-4DD1-83D5-71DE70CD2D1A
P2860
Zanamivir for influenza in adults and children: systematic review of clinical study reports and summary of regulatory comments
description
2014 nî lūn-bûn
@nan
2014 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Zanamivir for influenza in adu ...... summary of regulatory comments
@ast
Zanamivir for influenza in adu ...... summary of regulatory comments
@en
Zanamivir for influenza in adu ...... summary of regulatory comments
@nl
type
label
Zanamivir for influenza in adu ...... summary of regulatory comments
@ast
Zanamivir for influenza in adu ...... summary of regulatory comments
@en
Zanamivir for influenza in adu ...... summary of regulatory comments
@nl
prefLabel
Zanamivir for influenza in adu ...... summary of regulatory comments
@ast
Zanamivir for influenza in adu ...... summary of regulatory comments
@en
Zanamivir for influenza in adu ...... summary of regulatory comments
@nl
P2093
P2860
P31
P921
P3181
P356
P1433
P1476
Zanamivir for influenza in adu ...... summary of regulatory comments
@en
P2093
Carl J Heneghan
Igho Onakpoya
Matthew Thompson
Tom Jefferson
P2860
P3181
P356
10.1136/BMJ.G2547
P407
P433
P5008
P577
2014-04-09T00:00:00Z